https://www.selleckchem.com/PARP.html
There was no statistically significant difference in treatment response at 6 and 12months (RR 0.6 [0.26;1.43] and 0.8 [0.27;2.33]), respectively, as well as the incidence of infection episodes between MMF and CYC group (71.4% versus 70.45%, 0.05). The average direct medical expenditures per patient in the MMF group were approximately one and half times more than the CYC group (2339.69 $ versus 1329.03 $, 0.001). The CYC arm was associated with lower costs than the MMF arm, with equally effective outcomes indicating that CYC is an attractiv
Like
Comment
Share
